Cassava Sciences Inc (SAVA)
$14.92
2.17 (17.02%)
SAVA Stock Quote Delayed 30 Minutes
SAVA Stock Alert: Cassava Sciences Pops on Late-Stage Trial Update
Cassava Sciences stock is up on Monday after the company provided SAVA investors with an update on its upcoming clinical trial data.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
626.19M
PE Ratio
-23.68
EPS
-0.63
Volume (Avg. Vol.)
3.66M
Day's Range
$12.86 - $14.94
52-Week Range
$8.79 - $32.10
Dividend & Yield
N/A (N/A)
SAVA Stock Predictions, Articles, and Cassava Sciences Inc News
SAVA Stock Alert: Former Cassava Science Advisor Charged With Fraud
SAVA stock is trading lower after a scientist behind Cassava's simufilam was charged with manipulating research data to justify his grants.
Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich
These three biotech stocks to buy carry risks but may appeal to speculative investors with time and patience.
SAVA Stock Earnings: Cassava Sciences Beats EPS for Q1 2024
SAVA stock results show that Cassava Sciences beat analyst estimates for earnings per share the first quarter of 2024.
Cassava Sciences (SAVA) Stock Pops on Positive Results in Simufilam Trial
SAVA stock jumped 9% on Wednesday after Casava Sciences shared promising results of a clinical trial of its Alzheimer's treatment.
Portfolio Protection: 7 Risky Stocks to Drop Right Now
Ahead of further or unforeseen challenges, if you own any of these seven risky stocks, now's the time to bail.
New SAVAW Warrants Are Trading After Cassava Sciences’ Distribution
Following a distribution, investors in Cassava Sciences and SAVA stock now have some warrants to factor into their models today.
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
Although Cassava Sciences’ issuance of warrants presents risks, the underlying Phase 3 trial support boosted SAVA stock.
SAVA Stock Continues to Plunge on Misconduct Allegations
An investigation into one of Cassava Sciences' advisors is pushing shares down. Here's why investors should worry about SAVA stock.
SAVA Stock Alert: Cassava Sciences Addresses Leaked Report
SAVA stock is falling hard following the publication of a City University of New York report by Science regarding Hoau-Yan Wang.
The 7 Best Meme Stocks to Buy Now: September 2023
Let's take a look at seven past and present favorites of the Reddit set, each of which should be considered one of the best meme stocks to buy right now.
Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock
Cassava is still enrolling patients in its Phase 3 study of the drug, which has a different target than Biogen's Leqembi.
Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results
Cassava Sciences (SAVA) stock is down 11% on underwhelming results from its clinical trials for its Alzheimer's treatment.
